Perrigo | PRGO - Des Atouts





Des Atouts Changement Date
AbbVie USD 133.96B 62M 2025-12
Abbott USD 86.71B 2.53B 2025-12
Bayer EUR 104.54B 331M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Coherus Biosciences USD 258.34M 258.18M 2025-12
Corcept Therapeutics USD 836.65M 13.04M 2025-12
Dr.Reddys Laboratories INR 562.9B 20.89B 2025-12
Eli Lilly USD 112.48B 2.46B 2025-12
J&J USD 200.89B 1.68B 2026-03
Merck USD 129.55B 12.02B 2025-09
Nestle CHF 127.15B 2.97B 2025-12
Pacira USD 1.26B 32.66M 2025-12
Perrigo USD 8.54B 1.55B 2025-12
Pfizer USD 208.73B 2.64B 2025-09
Phibro Animal Health USD 1.41B 20.03M 2025-12
Prestige Brands USD 3.49B 52.46M 2025-12
Reckitt Benckiser GBP 25.3B 1.11B 2024-12
Sanofi EUR 128.02B 1.22B 2026-03
Supernus Pharmaceuticals USD 1.45B 32.89M 2025-12
Teva Pharmaceutical Industries USD 40.75B 892M 2025-12
Xeris Pharmaceuticals USD 383.53M 13.34M 2025-12
Zoetis USD 15.47B 308M 2025-12